Leading trans health bodies say NHS puberty blocker trial breaches ethical norms

Three of the world’s leading professional organisations in transgender healthcare have warned that the UK’s planned NHS puberty blocker trial risks breaching international ethical standards and jeopardising the wellbeing of trans young people.

The European, World and US Professional Associations for Transgender Health (EPATH, WPATH and USPATH) issued a joint statement raising “significant ethical concerns” about the NHS PATHWAYS study, a £10 million trial commissioned after the UK Government’s decision to impose an indefinite ban on puberty blockers for trans minors outside of research settings.

The study will involve 220 young people, half of whom will receive puberty blockers, and will monitor their physical, social and emotional wellbeing. Under the current design, participants under 16 must undergo more than 13 hours of medical assessments before being considered for treatment — a process campaigners, clinicians and advocates have described as “intrusive and distressing” for vulnerable adolescents seeking gender-affirming care.

In their statement, released Friday 9 January, EPATH, WPATH and USPATH set out five principal concerns about the trial’s design and implementation.

Central among these is the risk to voluntary informed consent. Because the PATHWAYS trial is presently the only route to publicly funded access to puberty blockers for trans young people in the UK, the organisations argue that families may feel pressured to enrol, undermining the voluntariness that is fundamental to ethical research.

They also warn that requiring adolescents who already meet established clinical criteria for puberty suppression to wait longer for care could violate “established clinical guidelines” and expose them to preventable distress. Delaying access to puberty blockers for eligible young people, they argue, effectively prioritises data collection over the protection of participants’ health.

The statement further criticises the trial framework for failing to adequately centre the “lived experience” of trans youth as a core element of both ethical and clinically robust research. The organisations insist that young people’s voices, and those of their families, must be integral to the design and evaluation of any study that directly affects their lives and identities.

EPATH, WPATH and USPATH also call on the UK Government not to treat the PATHWAYS findings as a “sole basis” for national policy on trans youth healthcare, warning that the current design could produce results distorted by restricted access and delayed treatment.

They caution that, in its present form, the research risks placing “research objectives over patient well-being” by making timely care conditional on participation in a lengthy and demanding trial.

“Ethical research must be voluntary, clinically sound, and designed with the well-being of participants at its core,” the statement reads. “We welcome opportunities for collaboration that uphold these principles and advance the health and rights of transgender young people.”

The concerns from leading professional bodies come amid growing evidence that the blanket ban on puberty blockers for trans youth outside research is causing serious harm.

Research published last year found that the prohibition was having “serious adverse effects” on trans adolescents, with several young people described by their parents as previously “well-adjusted” developing depression, anxiety and other mental health difficulties because they were unable to access gender-affirming medical care.

The human cost of delayed treatment was highlighted by Caroline Litman, mother of trans teenager Alice, who died by suicide while waiting for NHS gender care. Speaking about the PATHWAYS trial, she condemned the current approach: “This is not health care. The old ‘watch and wait’ is how Alice was treated.”

During a House of Commons debate, Health Secretary Wes Streeting defended the Government’s position, claiming ministers were following “clinical advice” in maintaining the ban outside of research and insisting that the PATHWAYS trial would meet the “highest standards of ethics”.

However, major medical and human rights bodies internationally continue to affirm that puberty blockers, when used under specialist supervision, are a safe and reversible intervention that can significantly reduce distress for trans adolescents. There is virtually no reliable evidence that puberty suppression poses inherent risks to trans young people, and the medications remain routinely available in the UK for cisgender children experiencing precocious (early) puberty.

LGBTQ+ advocates and clinical experts argue that this double standard — restricting puberty blockers for trans youth while freely providing them to cisgender children — reflects political pressure rather than evidence-based medicine, and risks further marginalising an already vulnerable population.